PharmatecaPharmatecaФарматека2073-40342414-9128Bionika Media278145ArticlesСтатьиBronchial asthma, Chlamydophila pneumoniae infection and macrolides: discussion is continuingБРОНХИАЛЬНАЯ АСТМА, ИНФЕКЦИЯ CHLAMYDOPHILA PNEUMONIAE И МАКРОЛИДЫ: ДИСКУССИЯ ПРОДОЛЖАЕТСЯBelotserkovskayaYu GБелоцерковскаяЮ Г

Государственный институт усовершенствования врачей МО РФ, Москва

Sinopal'nikovA IСинопальниковА И

Государственный институт усовершенствования врачей МО РФ, Москва

BelocerkovskayaYu GSinopalnikovA IГосударственный институт усовершенствования врачей МО РФ, Москва151020091619NO19 (2009)№19 (2009)425123022023Copyright ©; 2009, Bionika MediaCopyright ©; 2009, ООО «Бионика Медиа»2009Bionika MediaООО «Бионика Медиа»https://journals.eco-vector.com/2073-4034/article/view/278145

We found the pathogenetic importance of infection caused by Chlamydophila pneumoniae (CP-infection) in the development of bronchial asthma (BA). Increase of knowledge about the involvement of C. pneumoniae in the pathogenesis of asthma has led to particular changes in approaches to the asthma treatment. We present evidence that macrolide antibiotics have a beneficial impact on the course of asthma. The results of the study, whose goal was evaluation of possibility of optimization the asthma control based on determination of chronic persistent CP infection influence on the natural history of disease and evaluation of effectiveness of prolonged treatment with azithromycin in 71 patients with asthma, are presented. It is found that identification of chronic persistent CP infection can serve as a marker of severity of asthma, along with the degree of bronchial obstruction and the frequency of daily symptoms. Treatment with azithromycin promoted significant respiratory function improvement in patients with confirmed CP infection and some improvement in control of asthma.

Обосновывается патогенетическое значение инфекции, вызванной Chlamydophila pneumoniae (СР-инфекция) в развитии бронхиальной астмы (БА). Расширение знаний об участии C. pneumoniae в патогенезе БА привело к определенному изменению взглядов на лечение астмы. Представлены доказательства способности макролидных антибиотиков оказывать благоприятное воздействие на течение БА. Рассматриваются результаты исследования, целью которого явилось изучение возможности оптимизации контроля БА на основе установления влияния хронической персистирующей СР-инфекции на естественное течение заболевания и оценки эффективности длительной терапии азитромицином у 71 пациента с БА. Установлено, что выявление хронической персистирующей СР-инфекции может служить маркером тяжелого течения БА наряду со степенью бронхиальной обструкции и частотой ежедневных симптомов заболевания. Лечение азитромицином способствовало достоверному улучшению функции внешнего дыхания у больных с подтвержденной СР-инфекцией и некоторому улучшению контроля над БА.

Chlamydophila pneumoniaebronchial asthmaChlamydophila pneumoniaerespiratory functionmacrolidesazithromycinбронхиальная астмафункция внешнего дыханиямакролидыазитромицинЧучалин А.Г. Тяжелые формы бронхиальной астмы // Consilium Medicum. 2000. № 10. С. 51-55.Дрожжев М.Е., Лев Н.С., Костюченко М.В. и др. Современные показатели распространенности бронхиальной астмы среди детей // Пульмонология. 2002. № 1.С. 42-46.Biscione GL, Corne J, Chauhan AJ, et al. Increased frequency of detection of Chlamydophila pneumoniae in asthma. Eur Respir J 2004;24:745-49.Blasi F, Cosentini R, Tarsia P, et al. Atypical pathogens and asthma: can they influence the natural history of the disease? Monaldi Arch Chest Dis 2001;56:276-80.Sutherland ER, Martin RJ. Asthma and atypical bacterial infection. Chest 2007;132:1962-66.Rohde G, Rupp J. Infections and asthma. Internist (Berl) 2008;8:10-18.Hahn DL, Dodge RW, Golubjatnikov R. Association of Chlamydia pneumoniae (strain TWAR) infection with wheezing, asthmatic bronchitis, and adult-onset asthma. JAMA 1991;266:225-30.Hahn DL, McDonald R. Can acute Chlamydia pneumoniae respiratory tract infection initiate chronic asthma? Ann Allergy Asthma Immunol 1998;8:339-44.Von Hertzen L, Toyryla M, Gimishanov A, et al. Asthma, atopy and Chlamydia pneumoniae antibodies in adults. Clin Exp Allergy 1999;29:522-28.Hahn DL. Chlamydia pneumoniae, asthma and COPD: What is the evidence? Ann Allergy Asthma Immunol 1999;83:271-88.Von Hertzen L. Role of persistent infection in the control and severity of asthma: focus on Chlamydia pneumoniae. Eur Respir J 2002;19:546-56.Black PN, Scicchitano R, Jenkins CR. Serological evidence of infection with Chlamydia pneumoniae is related to the severity of asthma. Eur Respir J 2000;15:254-59.Miyashita N, Kubota Y, Nakajima M, et al. Chlamydia pneumoniae and exacerbations of asthma in adults. Ann Allergy Asthma Immunol 1998;80:405-09.Cosentini LR, Tarsia P, Canetta C, et al. Severe asthma exacerbation: role of acute Chlamydophila pneumoniae and Mycoplasma pneumoniae infection. Respiratory Research 2008;9:48-66.Евсюкова Е.В., Федосеев Г.Б., Савичева А.М. Хламидийная инфекция и аспириновая бронхиальная астма // Пульмонология. 2002. № 5. С. 64-68.Blasi F, Tarsia P, Aliberti S. Chlamydophila pneumonia. Clin Microbiol Infect 2009;15(1):29-35.Agarwal A, Chander Y. Chronic Chlamydia pneumoniae infection and bronchial asthma: is there a link? Indian J Med Microbiol 2008;26(4):338-41.Rottenberg ME, Rothfuchs AС, Gigliotti D, et al. Regulation and role of IFN- in the innate resistance to infection with Chlamydia pneumoniae. J Immunol 2000;64:4812-16.Benjamin W, Starcher BC, Samten B, et al. Multiple Chlamydia pneumoniae Antigens Prime CD8+ Tc1 Responses That Inhibit Intracellular Growth of This Vacuolar Pathogen. J Immunol 2002;169:2524-35.Yang J, Hooper WC, Phillips DJ, et al. Induction of Proinflammatory Cytokines in Human Lung Epithelial Cells during Chlamydia pneumoniae Infection Infect Immun 2003;71:614-20.Halme S, Latvala J, Karttunen R, et al. Cell-mediated innune response during primary Chlamydia pneumoniae infection. Infect Immun 2000;68:7156-58.Huittinen T, Hahn D, Anttila T, et al. Host immune response to Chlamidia pneumoniae heat shock protein 60 is assotiated with asthma. Eur Respir J 2001;17:1078-82.Blasi F, Tarsia P, Arosio C, et al. Epidemiology of Chlamydia pneumoniae. Clin Microbiol Infect 1998;4:1-6.Blasi F. Atipical pathogens and respiratory tract infections. Eur Respir J 2004;24:171-82.Crosbie PA, Woodhead MA. Long-term macrolide therapy in chronic inflammatory airway diseases. Eur Respir J 2009;33(1):171-81.La Shell MS, Tankersley MS. Antibiotics for the allergist: part 2. Ann Allergy Asthma Immunol 2009;102(1):1-7.Kamada AK, Hill MR, Ikle DN, et al. Efficacy and safety of low-dose troleandomycin therapy in children with severe, steroid-requiring asthma. J Allergy Clin Immunol 1993;91:873-82.Shoji T, Yoshida S, Sakamoto H, et al. Anti-inflammatory effect of roxithromycin in patients with aspirin-intolerant asthma. Clin Exp Allergy 1999;29:950-56.Amayasu H, Yoshida S, Ebana S, et al. Clarithromycin suppresses bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. Ann Allergy Asthma Immunol 2000;4:594-98.Black PN, Blasi F, Jenkins CR, et al. Trial of Roxithromycin in Subjects with Asthma and Serological Evidence of Infection with Chlamydia pneumoniae. Am J Respir Crit Care 2001;164:536-41.Kraft M, Cassell GH, Pak J, et al. Mycoplasma pneumoniae and Chlamydia pneumoniae in Asthma. Effect of Clarithromycin. Chest 2002;121:1782-88.Ekici A, Ekici M, Erdemoglu AK. Effect of azithromycin on the severity of bronchial hyperresponsiveness in patients with mild asthma. J Asthma 2002;39:181-85.Kostadima E, Tsiodras S, Alexopoulos EI, et al. Clarithromycin reduces the severity of bronchial hyperresponsiveness in patients with asthma. Eur Respir J 2004;23:714-17.Hahn DL, Plane MB, Mahdi OS, et al. Secondary Outcomes of a Pilot Randomized Trial of Azithromycin Treatment for Asthma. PLoS Clin Trials 2006;1:11-17.Hatipoglu U, Rubinstein I. Low-dose, long-term macrolide therapy in asthma: An overview. Clinical and Molecular Allergy 2004;2:1-4.Jahnz-Rozyk K, Targowski T. Atypical infection of the respiratory tract and bronchial asthma. Pol Merkur Lekarski 2007;23:325-27.Хамитов Р.Ф., Пальмова Л.Ю., Новоженов В.Г. Значение антибактериальной терапии при Chlamydophila pneumoniae инфекции у больных бронхиальной астмой // Терапевтический архив. 2004. № 10. С. 28-33.Beigelman A, Gunsten S, Mikols CL, et al. Azithromycin attenuates airway inflammation in a noninfectious mouse model of allergic asthma. Chest 2009;136(2):498-506.Hahn DL. Macrolide therapy in asthma: limited treatment, long-term improvement. Eur Respir J 2009;33(5):1239.Black PN. Antibiotics for the treatment of asthma. Curr Opin Pharmacol 2007;7:266-71.Kutlin А, Roblin PM, Hammerschlag R. Effect of Prolonged Treatment with Azithromycin, Clarithromycin or Levofloxacin on Chlamydia pneumoniae in a Continuous-Infection Model. Antimicrob. Agents Chemother 2002;2:409-2.Nathan RA, Sorkness CA, Kosinski M, et al. Development of the Asthma Control Test: A survey for assessing asthma control. J Allergy Clin Immunol 2004;113:59-65.Johnston SL, Martin RJ. Chlamydophila pneumoniae and Mycoplasma pneumoniae. A role in Asthma pathogenesis. Am J Respir Crit Care Med 2005;172:1078-89.Dowell SF, Peeling RW, Boman J, et al. Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada). Clin Infect Dis 2001;33:492-503.Shinkai M, Henke MO, Rubin BK. Macrolide antibiotics as immunomodulatory medications: Proposed mechanisms of action. Pharmacol Ther 2008;117:393-405.Глобальная стратегия лечения и профилактики бронхиальной астмы / Под ред. Чучалина А.Г. М., 2007. 104 с.Белевский А.С. Взгляд на пациента с точки зрения пациента: исследование INSPIRE // Consilium Medicum. 2007. № 3. С. 40-44.Bateman E, Boushey H, Bousquet J, et al. Achieving and maintaining guideline defined asthma control with salmeterol/fluticasone propionate versus fluticasone propionate alone: the results of the GOAL study. Am J Res Crit Care Med 2004;169:87-95.